{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:15:51Z","timestamp":1793506551329,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81930065"],"award-info":[{"award-number":["81930065"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173128"],"award-info":[{"award-number":["82173128"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017723","name":"Innovent Biologics","doi-asserted-by":"publisher","award":["TPS210"],"award-info":[{"award-number":["TPS210"]}],"id":[{"id":"10.13039\/100017723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2019-I2M-5-036"],"award-info":[{"award-number":["2019-I2M-5-036"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002002","name":"Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ccell.2024.07.004","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T10:43:23Z","timestamp":1722509003000},"page":"1570-1581.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial"],"prefix":"10.1016","volume":"42","author":[{"given":"Wei-Wei","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Hong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Zhong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Long","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Hai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Qiang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Mei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Tao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Zhong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-8534","authenticated-orcid":false,"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2024.07.004_bib1","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2024.07.004_bib2","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","article-title":"Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years","volume":"30","author":"Sauer","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib4","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib5","doi-asserted-by":"crossref","first-page":"e1555","DOI":"10.1002\/onco.13824","article-title":"Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis","volume":"26","author":"Liu","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ccell.2024.07.004_bib6","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib7","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2024.07.004_bib8","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2024.07.004_bib9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S2468-1253(22)00439-3","article-title":"Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study","volume":"8","author":"Chen","year":"2023","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ccell.2024.07.004_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ccell.2024.07.004_bib13","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2024.07.004_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1149122","article-title":"Total neoadjuvant treatment and PD-1\/PD-L1 checkpoint inhibitor in locally advanced rectal cancer","volume":"14","author":"Xiao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ccell.2024.07.004_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2024.07.004_bib16","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2024.07.004_bib17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2024.07.004_bib18","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","article-title":"Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer","volume":"28","author":"Bando","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2024.07.004_bib19","doi-asserted-by":"crossref","first-page":"TPS727","DOI":"10.1200\/JCO.2019.37.4_suppl.TPS727","article-title":"NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer","volume":"37","author":"George","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib20","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2021.39.15_suppl.3607","article-title":"A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study first-stage","volume":"39","author":"Tamberi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13014-020-01673-6","article-title":"Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma","volume":"15","author":"Shamseddine","year":"2020","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib22","article-title":"Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ccell.2024.07.004_bib23","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/JCO.2021.39.15_suppl.3511","article-title":"Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study","volume":"39","author":"Salvatore","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib24","doi-asserted-by":"crossref","first-page":"e15603","DOI":"10.1200\/JCO.2022.40.16_suppl.e15603","article-title":"The clinical efficacy and safety of neoadjuvant chemoradiation therapy with immunotherapy for the organ preservation of ultra low rectal cancer: A single arm and open label exploratory study","volume":"40","author":"Zhou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib25","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s12885-022-09554-9","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ccell.2024.07.004_bib26","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","article-title":"Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial","volume":"7","author":"Rahma","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2023.41.4_suppl.7","article-title":"Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)","volume":"41","author":"George","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib28","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2022.40.16_suppl.3609","article-title":"PKUCH 04 trial: Total neoadjuvant chemoradiation combined with neoadjuvant PD-1 blockade for pMMR\/MSS locally advanced middle to low rectal cancer","volume":"40","author":"WU","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12885-022-09348-z","article-title":"Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH)","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ccell.2024.07.004_bib30","first-page":"S410","article-title":"Short-course radiotherapy based total neoadjuvant therapy combined with PD-1 inhibitor for locally advanced rectal cancer: Preliminary findings of TORCH","volume":"34","author":"Wang","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2023.41.4_suppl.134","article-title":"Efficacy and safety of neoadjuvant preoperative short-course radiation followed by envafolimab plus CAPEOX in microsatellite stable (MSS)\/mismatch repair proficient (pMMR) locally advanced rectal cancer cancer","volume":"41","author":"Dai","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","article-title":"Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination","volume":"7","author":"Grapin","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ccell.2024.07.004_bib33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2021.10.003","article-title":"Radiotherapy and immunotherapy: open questions and future strategies","volume":"8","author":"Pointer","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ccell.2024.07.004_bib35","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41571-019-0238-9","article-title":"Assessing the interactions between radiotherapy and antitumour immunity","volume":"16","author":"Grassberger","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib36","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.7150\/jca.23874","article-title":"Long-Term Outcome of Oxaliplatin and Capecitabine (XELOX) Concomitant with Neoadjuvant Radiotherapy and Extended to the Resting Period in High Risk Locally Advanced Rectal Cancer","volume":"9","author":"Tang","year":"2018","journal-title":"J.\u00a0Cancer"},{"key":"10.1016\/j.ccell.2024.07.004_bib37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40880-018-0342-8","article-title":"Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid\/low rectal cancer: a long-term analysis of a prospective, single-center, randomized trial","volume":"38","author":"Wang","year":"2018","journal-title":"Cancer Commun."},{"key":"10.1016\/j.ccell.2024.07.004_bib38","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ijrobp.2014.07.021","article-title":"Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial","volume":"90","author":"Gao","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ccell.2024.07.004_bib39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.2022.40.4_suppl.117","article-title":"SONCAR study: A prospective randomized controlled study on optimized neoadjuvant chemotherapy-oxaliplatin plus CRT in patients with locally advanced rectal cancer","volume":"40","author":"Zhang","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib40","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.18.02309","article-title":"Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial","volume":"37","author":"Deng","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib41","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1200\/JCO.20.01932","article-title":"Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer","volume":"38","author":"Zhu","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib42","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.radonc.2018.08.027","article-title":"Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trial","volume":"129","author":"Wang","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.21147\/j.issn.1000-9604.2020.03.11","article-title":"Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019","volume":"32","author":"Weng","year":"2020","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.ccell.2024.07.004_bib44","doi-asserted-by":"crossref","first-page":"S1266","DOI":"10.1016\/j.annonc.2023.10.017","article-title":"LBA25 Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: A randomized phase III trial (UNION)","volume":"34","author":"Zhang","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.radonc.2020.03.011","article-title":"Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial","volume":"147","author":"van der Valk","year":"2020","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib46","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.trsl.2015.06.019","article-title":"Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer","volume":"166","author":"Teng","year":"2015","journal-title":"Transl. Res."},{"key":"10.1016\/j.ccell.2024.07.004_bib47","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.ijrobp.2017.07.004","article-title":"Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8+ Tumor-Infiltrating Lymphocytes Identified Patients With Poor Prognosis in Rectal Cancer: A Matched Comparison Analysis","volume":"99","author":"Lim","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ccell.2024.07.004_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2148374","article-title":"Comprehensive evaluation of the tumor immune microenvironment and its dynamic changes in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy: From the phase II ADORE study","volume":"11","author":"Cho","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ccell.2024.07.004_bib49","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41379-018-0114-7","article-title":"Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas","volume":"32","author":"Liu","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ccell.2024.07.004_bib50","article-title":"CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer","volume":"9","author":"Peng","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ccell.2024.07.004_bib51","first-page":"e20","article-title":"Stromal PD-1\/PD-L1 Expression Predicts Outcome in Colon Cancer Patients","volume":"18","author":"Wyss","year":"2019","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.ccell.2024.07.004_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103147","article-title":"A meta-analysis of CD274 (PD-L1) assessment and prognosis in colorectal cancer and its role in predicting response to anti-PD-1 therapy","volume":"157","author":"Alexander","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ccell.2024.07.004_bib53","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00432-019-02942-y","article-title":"PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1","volume":"145","author":"Ho","year":"2019","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib54","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2021.39.15_suppl.3584","article-title":"A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer","volume":"39","author":"Garralda","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib55","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1200\/JCO.2020.38.15_suppl.4044","article-title":"TAS-116, an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: An open-label, dose-finding, and expansion phase Ib trial (EPOC1704)","volume":"38","author":"Kawazoe","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib56","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.2024.42.3_suppl.124","article-title":"First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2\/3 study","volume":"42","author":"Xu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib57","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/modpathol.2016.95","article-title":"PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes","volume":"29","author":"Rosenbaum","year":"2016","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ccell.2024.07.004_bib58","doi-asserted-by":"crossref","first-page":"9647","DOI":"10.3390\/curroncol30110699","article-title":"The Predictive Value of CD3+\/CD8+ Lymphocyte Infiltration and PD-L1 Expression in Colorectal Cancer","volume":"30","author":"Liu","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113277","article-title":"PD-L1 Expression in High-Risk Early-Stage Colorectal Cancer-Its Clinical and Biological Significance in Immune Microenvironment","volume":"23","author":"Chung","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ccell.2024.07.004_bib60","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa2303269","article-title":"Preoperative Treatment of Locally Advanced Rectal Cancer","volume":"389","author":"Schrag","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2024.07.004_bib61","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1111\/cas.15039","article-title":"Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer","volume":"112","author":"Zhang","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ccell.2024.07.004_bib62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13014-021-01746-0","article-title":"The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy","volume":"16","author":"Wang","year":"2021","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib63","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.ccell.2024.07.004_bib64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2024.07.004_bib65","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1093\/nar\/gks042","article-title":"Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation","volume":"40","author":"McCarthy","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccell.2024.07.004_bib66","first-page":"1438","article-title":"From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline","volume":"5","author":"Chen","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.ccell.2024.07.004_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687975","article-title":"IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures","volume":"12","author":"Zeng","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ccell.2024.07.004_bib68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2024.07.004_bib69","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation"},{"key":"10.1016\/j.ccell.2024.07.004_bib70","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2024.07.004_bib71","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2024.07.004_bib72","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(09)70381-X","article-title":"Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial","volume":"11","author":"Chua","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2024.07.004_bib73","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(15)00004-2","article-title":"Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial","volume":"16","author":"Garcia-Aguilar","year":"2015","journal-title":"Lancet Oncol."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610824002691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610824002691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:05:56Z","timestamp":1762549556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610824002691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":71,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1535610824002691"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2024.07.004","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2024.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}